ProPhase Labs Stock (NASDAQ:PRPH)
Previous Close
$0.76
52W Range
$0.66 - $7.48
50D Avg
$2.08
200D Avg
$3.85
Market Cap
$18.26M
Avg Vol (3M)
$105.70K
Beta
-0.10
Div Yield
-
PRPH Company Profile
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
PRPH Performance
Peer Comparison
Ticker | Company |
---|---|
GTH | Genetron Holdings Limited |
XGN | Exagen Inc. |
LMDX | LumiraDx Limited |
SERA | Sera Prognostics, Inc. |
ENZ | Enzo Biochem, Inc. |
BNR | Burning Rock Biotech Limited |
PMD | Psychemedics Corporation |
DRIO | DarioHealth Corp. |
OLK | Olink Holding AB (publ) |
STRR | Star Equity Holdings, Inc. |
BDSX | Biodesix, Inc. |
INBS | Intelligent Bio Solutions Inc. |
PRPO | Precipio, Inc. |
STIM | Neuronetics, Inc. |
SHC | Sotera Health Company |